- NetraMark Holdings (AIAI) has announced the release of NetraGPT
- NetraGPT combines the power of NetraAI, the company’s proprietary AI/ML system, with generative pre-trained (GPT) models and large language model (LLM) APIs, to learn about unique combinations of variables that define patient subpopulations concerning drug response, adverse effects, and placebo response
- NetraMark can provide output reports within minutes, offering valuable insights and improving efficiency and explainability
- NetraMark is a software technology company dedicated to improving the understanding of how patients, within and across diseases, relate to each other
- NetraMark Holdings (CSE.AIAI) stocks opened today at $0.23
NetraMark Holdings (AIAI) has announced the release of NetraGPT.
NetraGPT is built upon the company’s proprietary AI/ML system, NetraAI, which has been validated with good clinical practice. The new algorithm of NetraGPT combines the power of NetraAI with generative pre-trained (GPT) models and large language model (LLM) APIs to revolutionize the analysis of patient subpopulations in clinical trials.
NetraAI is capable of learning about unique combinations of variables that define patient subpopulations concerning drug response, adverse effects, and placebo response.
With the integration of LLMs such as ChatGPT4 trained on vast amounts of medical literature, NetraMark can now provide output reports within minutes, offering valuable insights and improving the efficiency and explainability of its findings.
NetraGPT takes input from NetraAI, focusing on statistically significant variables associated with specific patient subpopulations. It then generates detailed human-readable reports by leveraging LLMs and referencing relevant medical literature. The transparency of the process allows experts to validate the hypotheses generated and ensure the accuracy of insights and recommendations.
Dr. Joseph Geraci, Founder and CTO/CSO of NetraMark, highlights the partnership between NetraAI and LLMs as a cutting-edge insight engine for clinical trial patient populations.
NetraMark is a software technology company dedicated to improving the understanding of how patients, within and across diseases, relate to each other. Its innovative AI/ML solutions offer powerful data analysis, segmentation of diseases, and patient classification, enabling accurate identification of treatment efficacy and drug sensitivity.
NetraMark Holdings (AIAI) opened today at $0.23.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.